Masayuki Shibasaki - Concepedia

Author

Masayuki Shibasaki

Astellas Pharma (Japan)

Also Known As

M Shibasaki, M. SHIBASAKI, M. Shibasaki, Masayuki SHIBASAKI, Masayuki Shibasaki, Moemi Shibasaki, Nauro Nishimura

160

Publications

3.5K

Citations

H-Index

127

Concepts

All Affiliations

Astellas Pharma (Japan)Kyoto Prefectural University of Medicine The University of Tokyo Astellas Pharma (Netherlands)Toyo University

About

Masayuki Shibasaki is an author at Astellas Pharma (Japan) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	43	1.8K
2	Health Sciences	14	19	1K
3	Engineering	4	4	53
4	Natural Sciences	2	2	53
5	Public Health	1	1	58

Masayuki Shibasaki

Publications

3.2K

Citations

H-Index

Page 1

	Year	Citations
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, European Journal of Pharmacology ObesityMetabolic SyndromeInflammationDiabetes ManagementMedicine	2013	305
Discovery of Novel Forkhead Box O1 Inhibitors for Treating Type 2 Diabetes: Improvement of Fasting Glycemia in Diabetic db/db Mice Takeyuki Nagashima, Nobuharu Shigematsu, Riyo Maruki, Molecular Pharmacology	2010	272
Prediction of Pediatric Endotracheal Tube Size by Ultrasonography Masayuki Shibasaki, Yasufumi Nakajima, Sachiyo Ishii, Anesthesiology	2010	231
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki, European Journal of Pharmacology	2014	190
Induction of high mobility group box-1 in dorsal root ganglion contributes to pain hypersensitivity after peripheral nerve injury Masayuki Shibasaki, Mika Sasaki, Mayumi Miura, Pain Peripheral Nerve InjuryPain MedicineImmunologyNeuropathic PainMolecular Pain	2010	129
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Journal of Pharmacy and Pharmacology	2014	122
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo Atsuo Tahara, Eiji Kurosaki, Masanori Yokono, Naunyn-Schmiedeberg s Archives of Pharmacology Anti-inflammatoryAllergyMedicinePharmacological AgentPharmacotherapy	2011	106
Ultrasound-Guided Radial Artery Catheterization in Infants and Small Children* Sachiyo Ishii, Nobuaki Shime, Masayuki Shibasaki, Pediatric Critical Care Medicine	2013	94
Application of fluorescent cholangiography to single-incision laparoscopic cholecystectomy Takeaki Ishizawa, Junichi Kaneko, Yosuke Inoue, Surgical Endoscopy Health SciencesMedical ImagingBiliary TractBiliary CancerGastroenterology	2011	75
Effects of antidiabetic drugs in high-fat diet and streptozotocin–nicotinamide-induced type 2 diabetic mice Atsuo Tahara, Akiko Matsuyama‐Yokono, Masayuki Shibasaki European Journal of Pharmacology Metabolic SyndromeDiabetes ManagementStreptozotocin–nicotinamide-induced Type 2DiabetesPhysiology	2011	70

Page 1